Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Erika Paige Hamilton

49PUBLICATIONS
446CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsClinical midwiferyHealth and ecological risk assessmentPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (49)

Sort by Publication Date:
|Jan 08, 2026
DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer.

Komal Jhaveri, Sherene Loi, Erika Hamilton

|Dec 17, 2025
ER degradation for ER<sup>+</sup>/HER2- advanced or metastatic breast cancer: a phase 1 trial.

Erika Hamilton, Rachel M Layman, David Cosgrove

|Dec 10, 2025
HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.

Veronique Dieras, Giuseppe Curigliano, Miguel Martin

|Nov 10, 2025
A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast Cancer.

Keith L Knutson, Hala Abu-Fares, Patricia Keating

|Nov 07, 2025
Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer.

Maxwell R Lloyd, Caroline M Weipert, Azka Ali

|Oct 27, 2025
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.

Dejan Juric, Kyung Song, Radia M Johnson

Pageof 9

Frequent Collaborators

7 joint publications

Miguel Martin

6 joint publications

Komal L Jhaveri

5 joint publications

Kevin Kalinsky

5 joint publications

Peter Schmid

4 joint publications

Hope S Rugo

4 joint publications

Kan Yonemori

4 joint publications

Mythili Shastry

4 joint publications

Sara Hurvitz

4 joint publications

Nadia Harbeck

4 joint publications

Javier Cortés

Frequent Collaborators

7 joint publications

Miguel Martin

6 joint publications

Komal L Jhaveri

5 joint publications

Kevin Kalinsky

5 joint publications

Peter Schmid

Top Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on : Dec 11, 2017

7.6K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on : Jul 25, 2020

7.8K
See more related videos

Top Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on : Dec 11, 2017

7.6K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on : Jul 25, 2020

7.8K
See more related videos